Multicenter Phase 1b/2 Trial of Nintedanib with TAS-102 in Patients with Metastatic Colorectal Cancer (mCRC) who had the progression or intolerant to standard therapies.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 19 Apr 2017
At a glance
- Drugs Nintedanib (Primary) ; Tipiracil/trifluridine
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms N-TASK FORCE
- 11 Oct 2016 Results of phase I part presented at the 41st European Society for Medical Oncology Congress
- 03 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology